ARCHIVES

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

This article is from The Cancer Letter archive.

Vol. 18 No. 03 | January 17, 1992

Download PDF Visit The Full Archive

Related Articles

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

July 30, 1999

The Cancer Letter To End Print Edition In January

November 20, 2009

NCAB Committee Still Debating How To Encourage Surgical Oncology

April 26, 1985

National Action Plan Issues Complete List Of Breast Cancer Funding Mechanisms

May 26, 1995

PET Three Months After Therapy Provides Early Warning Of Need For Intervention

November 30, 2007

Firm To Collaborate With R. W. Johnson On Vaccines.

December 1, 2000